Methods for treating cyclophilin D-associated diseases

Antisense oligomers target the PPIF gene transcript to induce exon skipping, effectively reducing cyclophilin D protein levels and ameliorating cyclophilin D-related diseases by producing non-functional proteins, overcoming the non-specific modulation of existing treatments.

JP2024541719AInactive Publication Date: 2024-11-11レゾナンス ヘルス アナリシス サービシーズ ピーティーワイ リミテッド
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024529487
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-18
Filing Date
2022-11-17
Publication Date
2024-11-11
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for cyclophilin D-related diseases, such as cyclosporine A, modulate cyclophilin proteins indiscriminately, affecting both beneficial and non-beneficial functions, necessitating a more targeted approach to regulate cyclophilin D levels.

Method used

The use of antisense oligomers to target and modify pre-mRNA splicing in the PPIF gene transcript, specifically inducing exon skipping or intron retention to reduce functional cyclophilin D protein expression.

Benefits of technology

This approach selectively reduces cyclophilin D protein levels, mitigating the effects of cyclophilin D-related diseases by altering splicing patterns to produce non-functional or truncated proteins, thereby addressing the limitations of existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541719000010
    Figure 2024541719000010
  • Figure 2024541719000011
    Figure 2024541719000011
  • Figure 2024541719000012
    Figure 2024541719000012
Patent Text Reader

Abstract

An isolated or purified antisense oligomer having an altered backbone structure for altering pre-mRNA splicing in a PPIF gene transcript or a portion thereof. In one aspect of the invention, an antisense oligomer of 10-50 nucleotides is provided that comprises a target sequence complementary to a region adjacent to or within an intron of a PPIF gene transcript or a portion thereof. In another aspect of the invention, an antisense oligomer of 10-50 nucleotides is provided that comprises a target sequence complementary to a region adjacent to or within an exon of a PPIF gene transcript or a portion thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Technical Field The present invention relates to the use of antisense oligomers to treat, prevent or ameliorate the effects of cyclophilin D associated diseases and pathologies. [Background technology]

[0002] Background technology Cyclophilin D (CYPD, PPIF) is a ubiquitously distributed protein belonging to the immunophilin family, whose members catalyze the cis-trans isomerization of proline-imide peptide bonds. In humans, the PPIF gene is located on chromosome 10 and encodes a 17.5 kDa protein of 207 amino acids containing six exons. In the context of mitochondria, CYPD is involved in the opening of the mitochondrial permeability transition pore (mPTP) (PubMed:26387735). Mitochondrial Ca 2 Under stress, such as increased influx, CYPD is thought to bind to the adenine nucleotide translocase (ANT) machinery to promote the opening of the mPTP pore. Thus, CYPD is considered a key mediator in the release of proapoptotic and other factors from mitochondria that lead to cell death.

[0003] Structurally, CYPD shows a high degree of homology to other members of the cyclophilin family in its core β-barrel / isomerase region, which contains a surface hydrophobic pocket that constitutes a proline-binding motif. Both the N- and C-termini of CYPD are significantly different from other members of the cyclophilin family.

[0004] CYPD has been shown to play important functions in a variety of human diseases, including ischemia-reperfusion-, oxidative-, inflammatory- and trauma-related injury (affecting the liver, brain, heart, lungs, pancreas and kidneys), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic diseases (NAFLD / NASH and obesity), skeletal muscle diseases, and inflammatory diseases.

[0005] Currently, CYPD is regulated in various diseases and pathologies by the administration of naturally occurring immunosuppressants such as cyclosporine A (CsA) and their derivatives known to be active against CYPD. However, the use of pan-cyclophilin inhibitors such as CsA or its synthetic derivatives may not be ideal, as they may result in the inactivation of cyclophilin members whose actions are beneficial and unrelated to the disease being treated.

[0006] There is a need to provide new therapeutic or preventative means for modulating the levels of CYPD both in specific tissues and throughout the body, or at least to provide methods that are complementary to previously known treatments. The present invention seeks to provide improved or alternative methods for treating, preventing or ameliorating the effects of diseases and pathologies associated with cyclophilin D.

[0007] The preceding description of the background art is intended only to facilitate an understanding of the present invention. The discussion is not an acknowledgment or admission that any of the material referred to was or was part of the common general knowledge at the priority date of the application. Summary of the Invention [Means for solving the problem]

[0008] Summary of the Invention Generally, according to one aspect of the invention, there is provided an isolated or purified antisense oligomer for altering pre-mRNA splicing in a PPIF gene transcript or a portion thereof, preferably for inducing non-productive splicing in a PPIF gene transcript or a portion thereof.

[0009] For example, one aspect of the present invention provides an antisense oligomer of 10 to 50 nucleotides that contains a target sequence complementary to a region adjacent to or within an intron of a PPIF gene transcript or a portion thereof. Another aspect of the present invention provides an antisense oligomer of 10 to 50 nucleotides that contains a target sequence complementary to a region adjacent to or within an exon of a PPIF gene transcript or a portion thereof.

[0010] Preferably, the antisense oligomer is selected from the group comprising the sequences shown in Table 3. Preferably, the antisense oligomer is selected from the list comprising SEQ ID NOs: 1-44, more preferably SEQ ID NO: 35 or 37.

[0011] The antisense oligomer preferably acts to induce skipping of one or more exons of the PPIF gene transcript or a portion thereof. For example, the antisense oligomer may induce skipping of exons 3 and / or 4.

[0012] The antisense oligomer of the present invention can be selected to be an antisense oligomer that can bind to a selected PPIF target site, the target site being an mRNA splicing site selected from a splice donor site, a splice acceptor site, or an exon splicing element. The target site may also include some adjacent intronic sequences when a donor or acceptor splice site is targeted.

[0013] More specifically, the antisense oligomer may be selected from the group including any one or more of SEQ ID NOs: 1-44, more preferably SEQ ID NOs: 35 or 37; and / or the sequences listed in Table 3, as well as combinations or cocktails thereof. This includes sequences capable of hybridizing to such sequences under stringent hybridization conditions, sequences complementary thereto, sequences containing modified bases that possess or modulate pre-mRNA processing activity in PPIF gene transcripts, modified backbones and functional truncations or extensions thereof. In certain embodiments, the antisense oligomer may be 100% complementary to the target sequence or may contain mismatches, for example to accommodate variants, so long as the heteroduplex formed between the oligonucleotide and the target sequence is sufficiently stable to withstand the action of cellular nucleases and other degradation modes that may occur in vivo. Thus, a particular oligonucleotide may have about or at least about 70% sequence complementarity between the oligonucleotide and the target sequence, e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence complementarity.

[0014] The present invention also extends to combinations of two or more antisense oligomers capable of binding to a selected target and inducing exon exclusion in the PPIF gene transcript, including constructs comprising two or more such antisense oligomers, which may be used in antisense oligomer-based therapy.

[0015] According to a still further aspect thereof, the present invention extends to cDNA or cloned copies of the antisense oligomer sequences of the invention, as well as vectors containing the antisense oligomer sequences of the invention. The present invention further extends to cells containing such sequences and / or vectors.

[0016] 1. A method for regulating splicing in a PPIF gene transcript, comprising: Also provided is a method comprising the steps of: a) providing one or more of the antisense oligomers described herein and allowing the oligomer to bind to a target nucleic acid site.

[0017] 1. A pharmaceutical, prophylactic or therapeutic composition for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression in a patient, comprising: a) one or more antisense oligomers as described herein; and b) one or more pharma- ceutically acceptable carriers and / or diluents; Also provided is a pharmaceutical, prophylactic, or therapeutic composition comprising:

[0018] The composition may contain about 1 nM to 1000 nM of each of the desired antisense oligomers of the present invention. Preferably, the composition may contain about 10 nM to 500 nM, and most preferably 1 nM to 10 nM, of each of the antisense oligomers of the present invention.

[0019] 1. A method for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression, comprising: Also provided are methods that include the step of: a) administering to a patient an effective amount of one or more antisense oligomers described herein, or a pharmaceutical composition comprising one or more antisense oligomers.

[0020] Also provided is the use of a purified and isolated antisense oligomer as described herein for the manufacture of a medicament for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression.

[0021] Also provided are kits for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression in a patient, comprising at least an antisense oligomer as described herein, and combinations or cocktails thereof, packaged in a suitable container together with instructions for use thereof.

[0022] Preferably, the disease or pathology associated with PPIF gene expression in the patient is selected from the list including ischemia-reperfusion-associated injury, oxidative-associated injury, inflammation-associated injury and trauma-associated injury (affecting the liver, brain, heart, lungs, pancreas and kidneys), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic diseases (NAFLD / NASH and obesity), skeletal muscle diseases, and inflammatory diseases.

[0023] A subject having a disease or pathology associated with PPIF gene expression can be a mammal, including a human. Further aspects of the present invention will now be described with reference to the accompanying non-limiting examples and figures.

[0024] BRIEF DESCRIPTION OF THE DRAWINGS Further features of the present invention will be described more fully in the following description of several non-limiting embodiments thereof. This description is included solely for the purpose of illustrating the present invention and should not be understood as a limitation on the broad summary, disclosure or description of the present invention set forth above. The following description will be made with reference to the accompanying drawings. [Brief description of the drawings]

[0025] [Figure 1]RT-PCR analysis of total RNA harvested from HepG2 cultures 24 h after transfection with ASOs (500 nM, synthesized with a 2-O-methyl backbone) designed to induce the skipping of exon 2 or 3 from the full-length CYPD mRNA sequence. Agarose gel electrophoresis (AGE) of the resulting PCR products showed that ASOs CDm2.1, CDm2.2, CDm2.3 and CDm2.5 (Figures 1a and 1b) induced the deletion of a 31 bp fragment, consistent with the size of exon 2, and ASOs CDm3.3 and CDm3.4 induced the deletion of an 89 bp fragment, consistent with the size of exon 3 (Figures 1b and 1c). A 100 bp molecular weight marker was loaded in the first lane. [Diagram 2] RT-PCR analysis of total RNA harvested from HepG2 cultures 24 h after transfection with ASOs (500 nM, synthesized with a 2-O-methyl backbone) designed to induce the skipping of exons 4 or 5 from the full-length CYPD mRNA sequence. Agarose gel electrophoresis (AGE) of the resulting PCR products showed that ASOs CDm4.3, CDm4.4, CDm4.5 and CDm4.7 (Figures 2a and 2b) each induced the deletion of a 97 bp fragment, consistent with the size of exon 4, and ASOs CDm5.3 and CDm5.4 induced the deletion of a 76 bp fragment, consistent with the size of exon 5 (Figures 2b and 2c). 100 bp molecular weight markers were loaded in the first and last lanes. [Diagram 3] RT-PCR analysis of total RNA taken from HepG2 cultures 24 h after transfection with ASOs (250 nM, synthesized with MOE backbone and called CDm3.41, CDm3.42, CDm3.43, CDm3.44 and CDm3.45) obtained by "microwalking" 5' and 3' of the CDm3.4 sequence. Agarose gel electrophoresis (AGE) of the PCR products (obtained using primers SEQ ID NO: 49 / 50) showed that each ASO induced a variable exon 3 deletion, with ASO CDm3.45 inducing an almost complete skipping. NTC indicates mock transfection control. A 100 bp molecular weight marker was loaded in the first lane. [Figure 4] RT-PCR analysis of total RNA taken from HepG2 cultures 24 h after transfection with ASOs (250 nM, synthesized with MOE backbone and called CDm4.41, CDm4.42, CDm4.43, CDm4.44 CDm4.45 and CDm4.46) obtained by "microwalking" 5' and 3' of the CDm4.4 sequence. Agarose gel electrophoresis (AGE) of the PCR products (obtained using primers SEQ ID NO: 49 / 50) showed that all ASOs induced substantial exon 4 deletion, while ASOs CDm4.4 and CDm4.41 induced almost complete skipping, as evidenced by the absence of residual FL CYPD mRNA. NTC indicates mock transfection control. A 100 bp molecular weight marker was loaded in the first lane. [Diagram 5] RT-PCR analysis of total RNA taken from HepG2 cultures 24 h after transfection with ASOs (250 nM, synthesized with MOE backbone and called CDm5.31, 5.32, 5.33, 5.34 and 5.32; and CDm5.41, 5.42 and 5.43) obtained by "microwalking" 5' and 3' of the CDm5.3 and 5.4 sequences. Agarose gel electrophoresis (AGE) of the PCR products (obtained using primers SEQ ID NO: 49 / 50) showed that all ASOs induced almost complete exon 5 deletions. NTC indicates mock transfection control. A 100 bp molecular weight marker was loaded in the first lane. [Figure 6]Effect of ASO treatment on CYPD mRNA and protein expression. A) RT-PCR of total RNA harvested from HepG2 cultures 24 hours after transfection with ASOs (250 nM, synthesized using MOE backbone) CDm3.45, CDm4.4, CDm4.41, CDm 5.4, CDm5.41, CDm5.42, CDm5.3, CDm5.31 and scrambled control ASO 953 showing deletion of either exon 3, 4 or 5 from full length CYPD mRNA: a) Agarose gel electrophoresis (AGE) of the PCR products (obtained using primers SEQ ID NOs: 48 and 49) showed deletion of a 94 bp fragment consistent with the expected size of exon 3, whereas ASO scrambled control 953 did not induce exon 3 skipping; b) Images of Western blots of lysates harvested 3 days after transfection and probed with anti-CYPD antibody; c) Plot showing percent CYPD band intensity (relative to total protein loading). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] Description of the invention Detailed Description of the Invention Antisense oligonucleotides Cyclophilin D (CYPD), also known as peptidyl prolyl isomerase F (PPIF), is an enzyme protein that in humans is encoded by the PPIF gene on chromosome 10. In this application, the terms CYPD and PPIF are used interchangeably to refer to the cyclophilin B gene and protein. Cyclophilin D referred to herein should not be confused with cyclophilin-40, also referred to as CYPD.

[0027] Expression of CYPD protein is associated with various inflammatory diseases and cancer. CYPD plays an important role in many disease-related processes that cause cardiovascular disease (cardiac arrest, ischemia-reperfusion injury), cerebrovascular disease (stroke, traumatic brain injury, spinal cord contusion, and ischemia-reperfusion injury), liver disease, kidney disease, diabetes, neurodegeneration (Alzheimer's disease, Parkinson's disease, ALS, traumatic brain injury, spinal cord injury, and multiple sclerosis), cancer, and aging.

[0028] Given the role of mitochondria in regulating cellular redox responses to external stimuli, CYPD is proinflammatory. CYPD has been detected in serum and can interact with the CD147 (the main cellular receptor for CYPD) receptor (in a manner similar to cyclophilin A and cyclophilin B) to induce chemotactic activity in macrophages, neutrophils and leukocytes.

[0029] Diseases and pathologies associated with expression of CYPD proteins can be found in the table below, along with the hypothesized mechanism of action elucidated in the respective studies carried out. [Table 1] [Table 2-1] [Table 2-2]

[0030] According to the first aspect of the present invention, an antisense oligomer is provided that can bind to a selected target on the PPIF gene transcript and modify pre-mRNA splicing in the PPIF gene transcript or a part thereof.In general, an isolated or purified antisense oligomer is provided for inducing targeted exon exclusion and / or terminal intron retention in the PPIF gene transcript or a part thereof.Preferably, an isolated or purified antisense oligomer is provided for inducing non-productive splicing in the PPIF gene transcript or a part thereof.

[0031] In the present invention, antisense oligomers are also known as antisense oligonucleotides, AOS, AONs and AONs, and these terms are interchangeable.

[0032] In one embodiment, there is provided an antisense oligomer of 10 to 50 nucleotides comprising a target sequence complementary to a region adjacent to or within an intron of the PPIF gene transcript or a portion thereof. In another embodiment, there is provided an antisense oligomer of 10 to 50 nucleotides comprising a target sequence complementary to a region adjacent to or within an exon of the PPIF gene transcript or a portion thereof.

[0033] In contrast to other antisense oligomer-based therapies, the present invention does not induce increased RNA degradation via recruitment of RNase H, which preferentially binds and degrades RNA duplex-bound to the DNA of the PPIF gene, and it does not depend on hybridization of the antisense oligomer to the PPIF genomic DNA or binding of the antisense oligomer to the mRNA, but rather regulates the amount of CYPD protein produced by interfering with normal functions such as replication, transcription, translocation and translation.

[0034] Rather, antisense oligomers are used to alter pre-mRNA splicing in the PPIF gene transcript or portions thereof, inducing exon "skipping" and / or terminal intron retention. This strategy preferably reduces total protein expression or produces a protein lacking a functional domain, resulting in reduced protein function.

[0035] "Isolated" refers to a material that is substantially or essentially free from components that are normally associated with it in its natural state. For example, "isolated polynucleotide" or "isolated oligonucleotide" as used herein can refer to a polynucleotide that has been purified or removed from adjacent sequences in its natural state, such as a DNA fragment that has been removed from adjacent sequences to the fragment in a genome. The term "isolate" with respect to a cell refers to the purification of a cell (e.g., a fibroblast, a lymphoblast) from a source subject (e.g., a subject with a polynucleotide repeat disease). In the context of mRNA or protein, "isolate" refers to the recovery of the mRNA or protein from a source, such as a cell.

[0036] An antisense oligomer can be said to be "directed" or "targeted" to the target sequence to which it hybridizes. In certain embodiments, the target sequence comprises a region containing the 3' or 5' splice site, branch point, or other sequence involved in regulating splicing of preprocessed mRNA. The target sequence may be within an exon or intron, or across an intron / exon junction.

[0037] In certain embodiments, the antisense oligomer has sufficient sequence complementarity to the target RNA (i.e., the RNA in which splice site selection is regulated) to block a region of the target RNA (e.g., a pre-mRNA) in an effective manner. In exemplary embodiments, such blocking of the PPIF pre-mRNA serves to regulate splicing by masking binding sites for native proteins that would otherwise regulate splicing and / or by altering the structure of the target RNA. In some embodiments, the target RNA is a target pre-mRNA (e.g., a PPIF gene pre-mRNA).

[0038] An antisense oligomer having sufficient sequence complementarity to a target RNA sequence to modulate splicing of a target RNA means that the antisense oligomer has sufficient sequence to cause masking of binding sites for native proteins that would otherwise modulate splicing and / or alter the three-dimensional structure of the target RNA.

[0039] The antisense oligomer selected can be shorter (e.g., about 12 bases) or longer (e.g., about 50 bases) and contain a small number of mismatches, so long as the sequence is sufficiently complementary to effect splice control upon hybridization with the target sequence and optionally forms a heteroduplex with RNA having a Tm of 45°C or greater.

[0040] Preferably, the antisense oligomer is selected from the group comprising the sequences shown in Table 3. Preferably, the antisense oligomer is selected from the group comprising the sequences of SEQ ID NOs: 1 to 44, more preferably SEQ ID NO: 35 or 37.

[0041] In certain embodiments, the degree of complementarity between the target sequence and the antisense oligomer is sufficient to form a stable duplex. The region of complementarity between the antisense oligomer and the target RNA sequence can be as short as 8-11 bases, but can be 12-15 bases or more, such as 10-50 bases, 10-40 bases, 12-30 bases, 12-25 bases, 15-25 bases, 12-20 bases, or 15-20 bases, including all integers between these ranges. An antisense oligomer of about 16-17 bases is generally long enough to have a unique complementary sequence. In certain embodiments, a minimum length of complementary bases may be required to achieve the required binding Tm, as discussed herein.

[0042] In certain embodiments, oligonucleotides as long as 50 bases may be suitable, with at least a minimum number of bases, e.g., 10-12 bases, being complementary to the target sequence.However, in general, enhanced or active uptake in cells is optimized at oligonucleotide lengths of less than about 30 bases.For example, for phosphorodiamidate morpholino oligomer (PMO) antisense oligomers, the optimal balance between binding stability and uptake generally occurs at lengths of 18-25 bases. Included are antisense oligomers consisting of about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 bases (e.g., CPP-PMO, PPMO, PMO, PMO-X, PNA, LNA, 2'-OMe, 2'MOE, 2'F oligomers, thiomorpholino and other hybrid oligomer chemistries). (PMO-phosphorodiamidate morpholino oligomer; CPP-cell penetrating peptide; PPMO-peptide conjugated phosphorodiamidate morpholino oligomer; PNA-peptide nucleic acid; LNA-locked nucleic acid; 2'-OMe-2'O-methyl modified oligomer; 2'MOE-2'-O-methoxyethyl oligomer, 2'F-2'fluoro)

[0043] In certain embodiments, antisense oligomers can be 100% complementary to target sequence, or can contain mismatches, for example, to accommodate variants, as long as the heteroduplex formed between oligonucleotide and target sequence is stable enough to withstand the action of cellular nucleases and other degradation modes that may occur in vivo.Thus, certain oligonucleotides can have about or at least about 70% sequence complementarity, for example, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence complementarity between oligonucleotide and target sequence.

[0044] Mismatches, if present, are typically less destabilizing toward the end regions of the hybrid duplex than toward the center. The number of mismatches tolerated depends on the length of the oligonucleotide, the percentage of G:C base pairs in the duplex, and the position of the mismatch in the duplex, according to well-understood principles of duplex stability. Although such antisense oligomers are not necessarily 100% complementary to the target sequence, they are effective in binding stably and specifically to the target sequence such that splicing of the target pre-RNA is modulated.

[0045] The stability of the duplex formed between the antisense oligomer and the target sequence is a function of the binding Tm and the susceptibility of the duplex to cellular enzymatic cleavage. The Tm of the oligonucleotide with respect to the complementary sequence RNA can be measured by conventional methods such as those described in Hames et al., Nucleic Acid Hybridization, IRL Press, 1985, pp. 107-108, or Miyada CG and Wallace RB, 1987, Oligonucleotide Hybridization Techniques, Methods Enzymol. Vol. 154 pp. 94-107. In certain embodiments, the antisense oligomer may have a binding Tm with respect to the complementary sequence RNA that is higher than body temperature, preferably higher than about 45°C or 50°C. Also included are Tms in the range of 60-80°C or higher.

[0046] Additional examples of variants include antisense oligomers having about or at least about 70% sequence identity, e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity, over the entire length of any of SEQ ID NOs: 1-44, more preferably SEQ ID NOs: 35 or 37, or the sequences provided in Table 3.

[0047] More specifically, antisense oligomers are provided that are capable of binding to a selected target site and altering pre-mRNA splicing in a PPIF gene transcript or a portion thereof, preferably selected from those provided in Table X or SEQ ID NOs: 1 to 44, more preferably SEQ ID NOs: 35 or 37.

[0048] The modification of pre-mRNA splicing preferably induces "skipping" or removal of one or more exons or introns of the mRNA and / or terminal intron retention. The resulting protein may be shorter in length due to either internal truncation or premature termination, or longer due to terminal intron retention, when compared to the parent full-length CYPD protein. These CYPD proteins may be referred to as isoforms of the unmodified CYPD protein.

[0049] The remaining exons of the generated mRNA may be in-frame, producing a shorter protein with a sequence similar to that of the parent full-length protein, except with an internal truncation in the region between the original 3' and 5' ends. In another possibility, exon skipping may induce a frameshift, resulting in a protein in which a first portion of the protein is substantially identical to the parent full-length protein, but a second portion of the protein has a different sequence (e.g., a nonsense sequence) due to the frameshift. Alternatively, exon skipping may induce the production of a prematurely terminated protein due to the disruption of the reading frame and the presence of a premature termination of translation. Additionally, antisense oligomers may produce artificially lengthened proteins due to in-frame terminal intron retention.

[0050] Since exons 2, 3, 4 and 5 encode key amino acids involved in the catalytic activity of CYPD, their deletion is expected to result in a non-functional enzyme. Furthermore, excision of exons 2 or 3 generates six or four premature stop codons, respectively, while excision of exons 4 or 5 generates four or three premature stop codons, respectively. Introduction of an aberrant stop codon into the mRNA would result in a non-functional, unstable, truncated polypeptide translation product. This truncated polypeptide would undergo rapid degradation, as evidenced by Western blot analysis of ASO-treated HepG2 cultures 3 days after transfection.

[0051] Removal of one or more exons can further result in misfolding of the CYPD protein and a reduction in the ability of the protein to be successfully transported across membranes.

[0052] The presence of an internally truncated protein (i.e., a protein lacking one or more amino acids encoded by exons) is preferred. If the CYPD protein is knocked out, there may be problems with increasing PPIF gene transcription, as the body tries to compensate for the reduction in the total amount of CYPD protein. In contrast, the presence of an internally truncated protein (preferably lacking one or more of the characteristics of the complete CYPD protein) should be sufficient to prevent the increase in transcription, but still provide therapeutic benefits due to the reduction in the total amount of functional CYPD protein.

[0053] The antisense oligomer-induced exon skipping of the present invention need not completely or substantially abolish the function of the CYPD protein, preferably the exon skipping process reduces or impairs the functionality of the CYPD protein.

[0054] The skipping process of the present invention using antisense oligomers may skip individual exons, or may skip two or more exons at a time.

[0055] The antisense oligomer of the present invention can be a combination of two or more antisense oligomers that can bind to a selected target and induce exon exclusion in the PPIF gene transcript. The combination can be a cocktail of two or more antisense oligomers and / or a construct that includes two or more antisense oligomers joined together. [Table 3-1] [Table 3-2]

[0056] 1. A method for regulating splicing in a PPIF gene transcript, comprising: Also provided is a method comprising the steps of: a) providing one or more of the antisense oligomers described herein and allowing the oligomer to bind to a target nucleic acid site.

[0057] According to yet another aspect of the present invention, there is provided a splice regulation target nucleic acid sequence for PPIF comprising the DNA equivalent of a nucleic acid sequence selected from the group consisting of Table 3 or SEQ ID NOs: 1 to 44, more preferably SEQ ID NO: 35 or 37, and a sequence complementary thereto.

[0058] Designing an antisense oligomer to completely mask consensus splice sites does not necessarily cause changes in the splicing of the target exon.Furthermore, the inventors have found that when designing an antisense oligomer, the size or length of the antisense oligomer itself is not necessarily the main factor.For some targets, such as IGTA4 exon 3, antisense oligomers as short as 20 bases can induce some exon skipping more efficiently than other longer (e.g. 25 bases) oligomers directed to the same exon in some cases.

[0059] We have also found that there appear to be no canonical motifs that can be blocked or masked by antisense oligomers to redirect splicing, and it has been found that antisense oligomers must be designed and their individual effectiveness empirically evaluated.

[0060] More specifically, the antisense oligomer may be selected from those shown in Table 3. The sequence is preferably selected from the group consisting of any one or more of SEQ ID NOs: 1-44, more preferably SEQ ID NOs: 35 or 37, and combinations or cocktails thereof. This includes sequences capable of hybridizing to such sequences under stringent hybridization conditions, sequences complementary thereto, sequences containing modified bases that possess or modulate pre-mRNA processing activity in PPIF gene transcripts, modified backbones and functional truncations or extensions thereof.

[0061] An oligomer and a DNA, cDNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides that can hydrogen bond with each other.Therefore, "specifically hybridizable" and "complementary" are terms used to indicate a sufficient degree of complementarity or pairing so that stable and specific binding occurs between an oligomer and a DNA, cDNA or RNA target.It is understood in the art that the sequence of an antisense oligomer does not need to be 100% complementary to the sequence of its target sequence that can specifically hybridize.An antisense oligomer can be specifically hybridized when there is a sufficient degree of complementarity to avoid non-specific binding of the antisense oligomer to non-target sequences when the binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA product, and under the conditions where specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatments, and under the conditions where the assay is performed in the case of in vitro assays.

[0062] Selective hybridization can be under low, medium or high stringency conditions, but is preferably under high stringency. Those skilled in the art will recognize that the stringency of hybridization is influenced by conditions such as salt concentration, temperature or organic solvents, in addition to base composition, length of complementary strands and number of nucleotide base mismatches between hybridizing nucleic acids. Stringent temperature conditions generally include temperatures above 30°C, typically above 37°C, preferably above 45°C, preferably at least 50°C, typically 60°C to 80°C or higher. Stringent salt conditions are usually less than 1000mM, typically less than 500mM, preferably less than 200mM. However, the combination of parameters is much more important than the measurement of any single parameter. An example of stringent hybridization conditions is 65°C and 0.1xSSC (1xSSC=0.15M NaCl, 0.015M sodium citrate pH 7.0). Thus, antisense oligomers of the invention can include sequences provided in Table 3, or oligomers that selectively hybridize to SEQ ID NOs:1-44, and more preferably to SEQ ID NOs:35 or 37.

[0063] It will be understood that the codon arrangement at the end of an exon in a structural protein may not necessarily be truncated at the end of the codon, and as a result, it may be necessary to delete more than one exon from the pre-mRNA to ensure in-frame reading of the mRNA. In such a situation, it may be necessary to select multiple antisense oligomers by the method of the present invention, each directed to a different region involved in inducing the inclusion of the desired exon and / or intron. At a given ionic strength and pH, Tm is the temperature at which 50% of the target sequence hybridizes to a complementary polynucleotide. Such hybridization may occur with "near" or "substantial" complementarity of the antisense oligomer to the target sequence, as well as exact complementarity.

[0064] Typically, selective hybridization occurs when there is at least about 55% identity with the nucleotide of antisense oligomer over a stretch of at least about 14 nucleotides, preferably at least about 65%, more preferably at least about 75%, most preferably at least about 90%, 95%, 98% or 99% identity.As described, the length of identity comparison can be over a longer stretch, and in certain embodiments, often over a stretch of at least about 9 nucleotides, usually at least about 12 nucleotides, more usually at least about 20, often at least about 21, 22, 23 or 24 nucleotides, at least about 25, 26, 27 or 28 nucleotides, at least about 29, 30, 31 or 32 nucleotides, at least about 36 or more nucleotides.

[0065] Therefore, the antisense oligomer sequence of the present invention preferably has at least 75%, more preferably at least 85%, more preferably at least 86, 87, 88, 89 or 90% identity to the sequence shown in the sequence listing herein. More preferably, there is at least 91, 92, 93, 94 or 95%, more preferably at least 96, 97, 98% or 99% identity. In general, the shorter the length of the antisense oligomer, the greater the identity required to obtain selective hybridization. As a result, when the antisense oligomer of the present invention is composed of less than about 30 nucleotides, the percentage identity is preferably more than 75%, preferably more than 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95%, 96, 97, 98% or 99% compared to the antisense oligomer described in the sequence listing herein. Nucleotide identity comparisons can be performed by sequence comparison programs such as the GCG Wisconsin Bestfit program or GAP (Deveraux et al., 1984, Nucleic Acids Research 12, 387-395). In this way, sequences of similar or substantially different length to those cited herein can be compared by inserting gaps into the alignment, such gaps being determined, for example, by the comparison algorithm used by GAP.

[0066] The antisense oligomers of the present invention may have regions of reduced identity and regions of exact identity to the target sequence. It is not necessary for the oligomer to have exact identity over its entire length. For example, the oligomer may have a continuous stretch of at least 4 or 5 bases identical to the target sequence, preferably a continuous stretch of at least 6 or 7 bases identical to the target sequence, more preferably a continuous stretch of at least 8 or 9 bases identical to the target sequence. The oligomer may have a stretch of at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 bases identical to the target sequence. The remaining stretches of the oligomer sequence may be intermittently identical to the target sequence. For example, the remaining sequence may have identical bases followed by non-identical bases followed by identical bases. Alternatively (or similarly), the oligomer sequence may have several stretches of identical sequence (e.g., 3, 4, 5 or 6 bases) interspersed with stretches of less than complete identity. Such sequence mismatches preferably result in little or no loss of splice switching activity, and even more preferably, such sequence mismatches result in increased translational regulatory activity.

[0067] The term "modulate" or "modulates" includes "increasing" or "decreasing" one or more quantifiable parameters by a defined and / or statistically significant amount, as appropriate. The terms "increase" or "increasing", "enhance" or "enhancing", or "stimulate" or "stimulating", or "augment" and "augmenting" generally refer to the ability of one or an antisense oligomer or composition to generate or cause a greater physiological response (i.e., a downstream effect) in a cell or subject compared to the response caused by no antisense oligomer or a control compound. The terms "decreasing" or "decrease" generally refer to the ability of an antisense oligomer or composition to produce or cause a decreased physiological response (i.e., a downstream effect) in a cell or subject compared to the response caused by no antisense oligomer or a control compound.

[0068] The relevant physiological or cellular response (in vivo or in vitro) will be apparent to one of skill in the art and may include an increase in the exclusion of a particular exon in the pre-mRNA encoding PPIF, a reduction in the amount of the pre-mRNA encoding PPIF, or a reduction in the expression of a functional CYPD protein in a cell, tissue, or subject in need thereof. A "decreased" or "reduced" amount is typically a statistically significant amount and may include a 1.1, 1.2, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50-fold or greater (e.g., 500-fold, 1000-fold) reduction (including all integers and decimals between and above 1, e.g., 1.5, 1.6, 1.7, 1.8) over the amount produced in the absence of the antisense oligomer (absence of drug) or when a control compound is used.

[0069] The term "reduce" or "inhibit" may generally refer to the ability of one or more antisense oligomers or compositions to "decrease" a relevant physiological or cellular response, such as a symptom of a disease or pathology described herein, as measured according to routine techniques in the diagnostic field. The relevant physiological or cellular response (in vivo or in vitro) will be apparent to one skilled in the art and may include a reduction in the symptoms of a disease or pathology, such as a disease selected from the list including ischemia-reperfusion-related injury, oxidative-related injury, inflammation-related injury and trauma-related injury (affecting the liver, brain, heart, lungs, pancreas and kidneys), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic disease (NAFLD / NASH and obesity), skeletal muscle disease, and inflammatory disease.

[0070] More preferably, the liver disease is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

[0071] More preferably, the renal disease is renal inflammation, acute kidney injury, renal fibrosis, or diabetic nephropathy.

[0072] A "reduction" in response may be statistically significant compared to the response provided by no antisense oligomer or a control composition and may include a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% reduction (including all integers in between).

[0073] The length of the antisense oligomer may vary so long as it is capable of selectively binding to the intended location within the pre-mRNA molecule. The length of such sequences can be determined according to the selection procedures described herein. Generally, the antisense oligomer is from about 10 to about 50 nucleotides in length. However, it will be understood that any length of nucleotide within this range can be used in the method. Preferably, the length of the antisense oligomer is 10-40, 10-35, 15-30 or 20-30 nucleotides in length, most preferably about 25-30 nucleotides in length. For example, the oligomer can be 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length.

[0074] As used herein, "antisense oligomer" refers to a linear sequence of nucleotides or nucleotide analogs that allows the nucleobases to hybridize to a target sequence in RNA by Watson-Crick base pairing to form an oligonucleotide:RNA heteroduplex within the target sequence. The terms "antisense oligomer," "antisense oligonucleotide," "oligomer," and "antisense compound" may be used interchangeably to refer to an oligonucleotide. The cyclic subunits may be based on ribose or another pentose sugar, or in certain embodiments, a morpholino group (see description of morpholino oligonucleotides below). Peptide nucleic acids (PNAs), locked nucleic acids (LNAs), and 2'-O-methyl oligonucleotides, among other antisense agents known in the art, are also contemplated.

[0075] Included are non-naturally occurring antisense oligomers or "oligonucleotide analogs" that include antisense oligomers or oligonucleotides having (i) modified backbone structures, e.g., backbones other than the standard phosphodiester linkages found in naturally occurring oligonucleotides and polynucleotides, and / or (ii) modified sugar moieties, e.g., morpholino moieties rather than ribose or deoxyribose moieties. Oligonucleotide analogs bear bases that can hydrogen bond to standard polynucleotide bases by Watson-Crick base pairing, and the analog backbone presents the bases in a manner that allows for such hydrogen bonding in a sequence-specific manner between the oligonucleotide analog molecule and the bases in a standard polynucleotide (e.g., single-stranded RNA or single-stranded DNA). Preferred analogs are those that have a substantially uncharged phosphorus-containing backbone.

[0076] One method for generating antisense oligomers is methylation of the 2' hydroxyribose position, and incorporation of a phosphorothioate backbone produces molecules that superficially resemble RNA but are much more resistant to nuclease degradation, although one of ordinary skill in the art of the present invention will recognize other forms of suitable backbones that may be used for the purposes of the present invention.

[0077] To avoid degradation of pre-mRNA and / or mRNA during duplex formation with antisense oligomers, the antisense oligomers used in the present method can be adapted to minimize or prevent cleavage by endogenous RNase H. This property is highly preferred, since treatment of RNA with unmethylated oligomers in cells or in crude extracts containing RNase H leads to degradation of pre-mRNA:antisense and / or mRNA:antisense oligomer duplexes. Any form of modified antisense oligomer that can bypass or cannot induce such degradation can be used in the present method. Nuclease resistance can be achieved by modifying the antisense oligomers of the present invention to include a partially unsaturated aliphatic hydrocarbon chain and one or more polar or charged groups, including carboxylic acid groups, ester groups, and alcohol groups.

[0078] Antisense oligomers that do not activate RNase H can be made according to known techniques (see, for example, U.S. Patent No. 5,149,797). Such antisense oligomers, which can be deoxyribonucleotide or ribonucleotide sequences, simply contain any structural modification that sterically prevents or prevents RNase H from binding to the duplex molecule that contains the oligomer as a member thereof, and the structural modification does not substantially prevent or disrupt duplex formation. Since the portion of the oligomer that participates in duplex formation is substantially different from the portion that participates in RNase H binding, a large number of antisense oligomers that do not activate RNase H are available. For example, such antisense oligomers can be oligomers in which at least one or all of the internucleotide bridge phosphate residues are modified phosphates, such as methyl phosphonates, methyl phosphorothioates, phosphoromorpholidates, phosphoropiperazidates, boranophosphates, amide bonds, and phosphoramidates. For example, every other internucleotide bridge phosphate residue can be modified as described. In another non-limiting example, such an antisense oligomer is a molecule in which at least one or all of the nucleotides contain a 2' lower alkyl moiety (e.g., C1-C4, straight or branched, saturated or unsaturated alkyl, e.g., methyl, ethyl, ethenyl, propyl, 1-propenyl, 2-propenyl, and isopropyl). For example, every other nucleotide can be modified as described.

[0079] An example of an antisense oligomer that is not cleaved by cellular RNase H when duplexed with RNA is a 2'-O-methyl derivative. Such 2'-O-methyl-oligoribonucleotides are stable in cellular environments and animal tissues, and their duplexes with RNA have higher Tm values ​​than their corresponding ribonucleotides or deoxyribonucleotides. Alternatively, the nuclease-resistant antisense oligomer of the present invention may have at least one last 3'-terminal nucleotide fluorinated. Still alternatively, the nuclease-resistant antisense oligomer of the present invention has phosphorothioate bonds linking at least two of the last three terminal nucleotide bases, and preferably phosphorothioate bonds linking the last four 3'-terminal nucleotide bases.

[0080] Increased splice switching can also be achieved by alternative oligonucleotide chemistries. For example, the antisense oligomer may be selected from the list including phosphoramidate or phosphorodiamidate morpholino oligomers (PMO, PMO-X, PPMO); peptide nucleic acid (PNA); locked nucleic acid (LNA) and derivatives including alpha-L-LNA, 2'-amino LNA, 4'-methyl LNA and 4'-O-methyl LNA; ethylene bridged nucleic acid (ENA) and their derivatives; phosphorothioate oligomers; tricyclo-DNA oligomers (tcDNA); tricyclophosphorothioate oligomers; 2'O-methyl modified oligomers (2'-OMe); 2'-O-methoxyethyl (2'-MOE); 2'-fluoro (2'F), 2'-fluoroarabino (FANA); unlocked nucleic acid (UNA); hexitol nucleic acid (HNA); cyclohexenyl nucleic acid (CeNA); 2'-amino (2'-NH2); 2'-O-ethyleneamine or any combination of the above as a mixmer or gapmer. To further improve delivery efficacy, the above-mentioned modified nucleotides are often conjugated to sugar or nucleobase moieties with fatty acids / lipids / cholesterol / amino acids / carbohydrates / polysaccharides / nanoparticles, etc. These conjugated nucleotide derivatives can also be used to construct exon skipping antisense oligomers. Antisense oligomer-induced splice modification of human PPIF gene transcripts has generally used either oligoribonucleotides, PNA, 2OMe or MOE modified bases on phosphorothioate backbones. Although 2OMeAO is used in oligo design, due to their efficient in vitro uptake when delivered as cationic lipoplexes, these compounds are susceptible to nuclease degradation and are not considered ideal for in vivo or clinical use. When alternative chemistry is used to generate the antisense oligomers of the present invention, uracil (U) in the sequences provided herein may be replaced with thymine (T).

[0081] While the antisense oligomers described above are preferred forms of antisense oligomers of the invention, the invention includes other oligomeric antisense molecules, including, but not limited to, oligomer mimetics as described below.

[0082] Specific examples of preferred antisense oligomers useful in the present invention include oligomers that contain modified backbones or non-natural internucleoside linkages.As defined herein, oligomers with modified backbones include those that retain phosphorus atom in backbones and those that do not have phosphorus atom in backbones.For the purpose of this specification, modified oligomers that do not have phosphorus atom in internucleoside backbones, as sometimes referred to in the art, can also be considered as antisense oligomers.

[0083] In other preferred oligomeric mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with appropriate nucleic acid target compounds. One such oligomeric compound, an oligomeric mimetic that has been shown to have excellent hybridization properties, is called a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of the oligomer is replaced with an amide-containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are directly or indirectly bound to the aza nitrogen atoms of the amide portion of the backbone.

[0084] Another preferred chemistry is phosphorodiamidate morpholino oligomer (PMO) oligomeric compounds that are not degraded by any known nucleases or proteases. These compounds are uncharged and do not activate RNase H activity when bound to an RNA strand.

[0085] Modified oligomers may also include one or more substituted sugar moieties. Oligomers may also include modifications or substitutions of nucleobases (often referred to in the art simply as "bases"). Certain nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil, and 5-propynylcytosine. 5-methylcytosine substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications, have been shown to increase nucleic acid duplex stability by 0.6-1.2°C.

[0086] Another modification of the oligomers of the invention involves chemically attaching to the oligomer one or more moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the oligomer. Such moieties include, but are not limited to, lipid moieties, such as cholesterol moieties, cholic acid, thioethers, such as hexyl-S-tritylthiol, thiocholesterol, aliphatic chains, such as dodecanediol or undecyl residues, phospholipids, such as di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, polyamines or polyethylene glycol chains, or adamantane acetic acid, palmityl moieties, myristyl, or octadecylamine or hexylamino-carbonyl-oxycholesterol moieties.

[0087] Cell-penetrating peptides have been added to phosphorodiamidate morpholino oligomers to enhance cellular uptake and nuclear localization. Different peptide tags have been shown to affect uptake efficiency and target tissue specificity, as shown by Jearawiriyapaisarn et al. (2008), Mol. Ther. 16 9, 1624-1629.

[0088] Not all positions of a given compound need be uniformly modified, and in fact more than one of the above modifications may be incorporated into a single compound or into a single nucleoside within an oligomer.The present invention also includes antisense oligomers that are chimeric compounds.A "chimeric" antisense oligomer or "chimera" in the context of the present invention is an antisense oligomer, particularly an oligomer, that contains two or more chemically distinct regions, each of which is composed of at least one monomer unit, i.e., in the case of an oligomeric compound, a nucleotide.These oligomers typically contain at least one region in which the oligomer is modified to provide the oligomer or antisense oligomer with an additional region for increased resistance to nuclease degradation, increased cellular uptake, and increased binding affinity to target nucleic acid.

[0089] The activity of antisense oligomers and their variants can be assayed according to routine techniques in the art. The expression level of the investigated RNA and protein can be evaluated by any of a wide variety of well-known methods for detecting the expression of transcribed nucleic acid or protein. Non-limiting examples of such methods include RT-PCR of spliced ​​forms of RNA followed by size separation of PCR products, nucleic acid hybridization methods such as Northern blots and / or nucleic acid arrays; nucleic acid amplification methods; immunological methods for detecting proteins; protein purification methods; and protein function or activity assays. Protein expression level can be evaluated by Western blots and / or ELISA assays from cells, tissues or organisms, and by evaluating downstream functional or physiological effects.

[0090] When two or more different sizes of transcripts are present, the resulting proteins can be evaluated by any of a wide variety of well-known methods for detecting the expression of related proteins.Non-limiting examples of such methods include immunological methods for detecting proteins; protein purification methods; mass spectrometry; and protein function or activity assays.

[0091] The present invention provides antisense oligomer-induced splice switching of PPIF gene transcripts to drive PPIF splice regulation to therapeutic levels, clinically relevant oligomer chemistry and delivery systems. A clinically relevant reduction in the amount of full-length PPIF mRNA, and therefore CYPD protein, from the PPIF gene transcript is achieved by: 1) in vitro oligomer refinement using fibroblast cell lines through experimental evaluation of (i) intronic enhancer targeting motifs, (ii) antisense oligomer length and oligomer cocktail development, (iii) chemistry selection, and (iv) addition of cell penetrating peptides (CPPs) to enhance oligomer delivery; and 2) A detailed evaluation of novel approaches to generate PPIF transcripts with one or more missing exons.

[0092] Therefore, it is demonstrated herein that the processing of PPIF pre-mRNA can be regulated by specific antisense oligomer.In this way, the amount of CYPD protein can be functionally significantly reduced, and thereby the serious diseases or pathologies related to PPIF gene expression are reduced, including ischemia-reperfusion-related damage, oxidation-related damage, inflammation-related damage and trauma-related damage (affecting liver, brain, heart, lung, pancreas and kidney), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic disease (NAFLD / NASH and obesity), skeletal muscle disease and inflammatory disease.

[0093] The antisense oligomer used according to the present invention can be conveniently produced by the well-known technique of solid phase synthesis.The equipment for such synthesis is sold by several vendors, including, for example, Applied Biosystems (Foster City, Calif.).One method for synthesizing oligomers on modified solid support is described in U.S. Patent No. 4,458,066.

[0094] Additionally or alternatively, any other means for such synthesis known in the art can be used.It is well known to use similar techniques to prepare oligomers such as phosphorothioates and alkylated derivatives.In one such automated embodiment, diethyl-phosphoramidite is used as starting material and can be synthesized as described by Beaucage, et al., (1981) Tetrahedron Letters, 22:1859-1862.

[0095] The antisense oligomers of the present invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense oligomers. The molecules of the present invention may also be mixed, encapsulated, conjugated or otherwise associated with other molecules, molecular structures or mixtures of compounds (e.g., liposomes, receptor-targeting molecules, etc.).

[0096] The antisense oligomers may be formulated for oral, topical, parenteral or other delivery, particularly formulations for injectable delivery. The formulations may be formulated to aid uptake, distribution and / or absorption at the site of delivery or activity.

[0097] Treatment According to yet another aspect of the present invention, one or more antisense oligomers as described herein are provided for use in antisense oligomer-based therapy.Preferably, the therapy is for a disease or pathology associated with PPIF gene expression.More preferably, the therapy for a disease or pathology associated with PPIF gene expression is a disease or pathology selected from the list of Table 1: ischemia-reperfusion-related injury, oxidation-related injury, inflammation-related injury and trauma-related injury (affecting the liver, brain, heart, lungs, pancreas and kidneys), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic disease (NAFLD / NASH and obesity), skeletal muscle disease, and inflammatory disease.

[0098] More preferably, the liver disease is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

[0099] More preferably, the renal disease is renal inflammation, acute kidney injury, renal fibrosis, and diabetic nephropathy.

[0100] Most preferably, the disease associated with PPIF gene expression in the patient is a liver disease selected from alcoholic liver disease (ALD), autoimmune hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatitis C, hepatitis B or hepatocellular carcinoma.

[0101] More specifically, the antisense oligomer may be selected from the group consisting of Table 3, or any one or more of SEQ ID NOs: 1-44, more preferably SEQ ID NO: 35 or 37, and combinations or cocktails thereof. This includes sequences capable of hybridizing to such sequences under stringent hybridization conditions, sequences complementary thereto, sequences containing modified bases that possess or modulate pre-mRNA processing activity in the PPIF gene transcript, modified backbones and functional truncations or extensions thereof.

[0102] The present invention also extends to a combination of two or more antisense oligomers capable of binding to a selected target and inducing exon exclusion in the PPIF gene transcript. The combination may be a cocktail of two or more antisense oligomers, a construct comprising two or more antisense oligomers joined together for use in antisense oligomer-based therapy.

[0103] Accordingly, there is provided a method for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression, comprising: Methods are provided that include the step of: a) administering to a patient an effective amount of one or more antisense oligomers described herein, or a pharmaceutical composition comprising one or more antisense oligomers.

[0104] Preferably, the disease or pathology associated with PPIF gene expression in the patient is selected from the list comprising ischemia-reperfusion-related injury, oxidative-related injury, inflammatory-related injury and trauma-related injury (affecting the liver, brain, heart, lungs, pancreas and kidneys), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic disease (NAFLD / NASH and obesity), skeletal muscle disease and inflammatory disease. More preferably, the disease or pathology is a liver disease selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or hepatocellular carcinoma.

[0105] Accordingly, the present invention provides a method for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression, comprising: a) administering to a patient an effective amount of one or more antisense oligomers described herein, or a pharmaceutical composition comprising one or more antisense oligomers.

[0106] Preferably, the treatment is used to reduce the level of functional CYPD protein via an exon skipping strategy. The reduction in the level of CYPD is preferably achieved by reducing the transcript level by modifying pre-mRNA splicing in the PPIF gene transcript or a part thereof.

[0107] The reduction in PPIF preferably results in a reduction in the amount, duration or severity of symptoms of a PPIF-associated disease or pathology, for example a disease or pathology associated with PPIF gene expression selected from the list including: ischemia-reperfusion-associated injury, oxidative-associated injury, inflammation-associated injury and trauma-associated injury (affecting the liver, brain, heart, lungs, pancreas and kidneys), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic diseases (NAFLD / NASH and obesity), skeletal muscle diseases, and inflammatory diseases.

[0108] As used herein, "treatment" of a subject (e.g., a mammal, such as a human) or cell is any type of intervention used to attempt to change the natural course of an individual or cell. Treatment includes, but is not limited to, the administration of a pharmaceutical composition, and may be performed prophylactically or after the onset of a pathological event or contact with a pathogen. It also includes "prophylactic" treatment, which may be directed to reducing the rate of progression of the disease or pathology being treated, delaying the onset of the disease or pathology, or reducing the severity of its onset. "Treatment" or "prophylaxis" does not necessarily indicate complete eradication, cure, or prevention of the disease or pathology, or its associated symptoms.

[0109] A subject having a disease or pathology associated with PPIF gene expression can be a mammal, including a human.

[0110] The antisense oligomers of the invention may also be used in combination with alternative treatments, such as drug treatments.

[0111] Thus, the present invention provides a method for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression, comprising administering the antisense oligomer of the present invention sequentially or simultaneously with another alternative therapy associated with treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression.Preferably, the disease or pathology is selected from the list including ischemia-reperfusion-related injury, oxidative-related injury, inflammatory-related injury and trauma-related injury (affecting the liver, brain, heart, lungs, pancreas and kidneys), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic disease (NAFLD / NASH and obesity), skeletal muscle disease and inflammatory disease.

[0112] delivery The antisense oligomer of the present invention can also be used as a prophylactic or therapeutic agent that can be utilized for the purpose of treating diseases or pathologies associated with PPIF gene expression.Thus, in one embodiment, the present invention provides an antisense oligomer that binds to a selected target in PPIF pre-mRNA and induces efficient and consistent exon skipping as described herein in a therapeutically effective amount mixed with a pharma-ceutically acceptable carrier, diluent or excipient.

[0113] 1. A pharmaceutical, prophylactic or therapeutic composition for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression in a patient, comprising: a) one or more antisense oligomers as described herein, and b) one or more pharma- ceutically acceptable carriers and / or diluents; Also provided is a pharmaceutical, prophylactic, or therapeutic composition comprising:

[0114] Antisense oligomers can be administered at regular intervals for a short period of time, for example, daily for 2 weeks or less.However, in many cases, oligomers are administered intermittently for a longer period of time.Subsequently or simultaneously, antibiotics or other therapeutic treatments can be administered.Treatment regimens can be adjusted as indicated (dosage, frequency, route, etc.) based on the results of immune assays, other biochemical tests and physiological tests of the subject under treatment.

[0115] Administration may depend on the severity and responsiveness of the disease state being treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a reduction in the disease state is achieved. Alternatively, administration may be titrated to the rate of progression of the disease. A baseline progression is established. The rate of progression after the first dose is then monitored to ensure that there is a reduction in the rate. Preferably, there is no progression after administration. Readministration is preferably only necessary if the rate of progression remains unchanged. Successful treatment preferably does not result in further progression of the disease or even some recovery of vision. Optimal administration schedules can be calculated from measurements of drug accumulation in the patient's body. Those skilled in the art can easily determine optimal dosages, administration methodologies and repetition rates.

[0116] Optimal dosages may vary depending on the relative potency of individual oligomers, and generally can be estimated based on the EC50 found to be effective in in vitro and in vivo animal models.

[0117] The repetition rate of administration depends on the progression rate of disease or pathology.Those skilled in the art can easily estimate the repetition rate of administration based on the measured residence time and the concentration of drug in body fluids or tissues.After successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent recurrence of disease state.

[0118] Effective in vivo treatment regimens using the antisense oligomers of the present invention may vary according to the duration, dose, frequency and route of administration, as well as the condition of the subject being treated (i.e., prophylactic administration versus administration in response to local or systemic infection).Thus, such in vivo therapy often requires monitoring with tests appropriate for the particular type of disorder being treated, and corresponding adjustment of the dose or treatment regimen to achieve optimal therapeutic results.

[0119] Treatment can be monitored, for example, by the general indicators of disease known in the art.The effectiveness of the in vivo administration antisense oligomer of the present invention can be determined from biological samples (tissue, blood, urine, etc.) taken from subjects before, during and after administration of antisense oligomer.The assay of such samples includes: (1) monitoring the presence or absence of heteroduplex formation by target sequence and non-target sequence using procedures known to those skilled in the art, for example, electrophoretic gel mobility assay; (2) monitoring the amount of mutant mRNA compared to reference normal mRNA or protein, as determined by standard techniques such as RT-PCR, Northern blotting, ELISA or Western blotting.

[0120] Nuclear oligomer delivery is a big challenge for antisense oligomers. Different cell penetrating peptides (CPPs) localize antisense oligomers to various degrees in different conditions and cell lines, and novel CPPs have been evaluated by the inventors for their ability to deliver antisense oligomers to target cells. The term CPP or "cell uptake enhancing peptide moiety" is used interchangeably and refers to cationic cell penetrating peptides, also called "transport peptides", "carrier peptides", or "peptide transduction domains". The peptides, as shown herein, have the ability to induce cell penetration within about or at least about 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the cells of a given cell culture population, allowing macromolecular translocation in multiple tissues in vivo upon systemic administration. CPPs are well known in the art and are disclosed, for example, in U.S. Patent Application No. 2010 / 0016215, which is incorporated by reference in its entirety.

[0121] Thus, the present invention provides an antisense oligomer of the invention in combination with a cell penetrating peptide to produce a therapeutic pharmaceutical composition.

[0122] Excipients The antisense oligomers of the present invention are preferably delivered in a pharma- ceutically acceptable composition. The composition may contain about 1 nM to 1000 nM of each of the desired antisense oligomers of the present invention. Preferably, the composition may contain about 1 nM to 500 nM, 10 nM to 500 nM, 50 nM to 750 nM, 10 nM to 500 nM, 1 nM to 100 nM, 1 nM to 50 nM, 1 nM to 40 nM, 1 nM to 30 nM, 1 nM to 20 nM, and most preferably 1 nM to 10 nM of each of the antisense oligomers of the present invention.

[0123] The composition may comprise about 1 nm, 2 nm, 3 nm, 4 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, 10 nm, 20 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 350 nm, 400 nm, 450 nm, 500 nm, 550 nm, 600 nm, 650 nm, 700 nm, 750 nm, 800 nm, 850 nm, 900 nm, 950 nm or 1000 nm of each of the desired antisense oligomers of the invention.

[0124] The present invention further provides one or more antisense oligomers adapted to aid in the prophylactic or therapeutic treatment, prevention or amelioration of symptoms of a disease, such as a disease or pathology associated with PPIF gene expression, in a form suitable for delivery to a patient.

[0125] The phrase "pharmaceutical acceptable" refers to molecular entities and compositions that are physiologically tolerable and typically do not cause allergic or similarly untoward reactions, such as stomach upset, when administered to a patient. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which a compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, such as those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water or saline and aqueous dextrose and glycerol solutions are preferably used as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in Remington: The Science and Practice of Pharmacy, 22nd Ed., Pharmaceutical Press, PA (2013).

[0126] In a more specific form of the present invention, pharmaceutical compositions are provided that comprise a therapeutically effective amount of one or more antisense oligomers of the present invention together with pharma- ceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and / or carriers. Such compositions include diluents of various buffer contents (e.g., Tris-HCI, acetate, phosphate), pH and ionic strength, as well as additives such as detergents and solubilizers (e.g., Tween® 80, polysorbate 80), antioxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). Materials can be incorporated into microparticle preparations of polymeric compounds such as polylactic acid, polyglycolic acid, or into liposomes. Hyaluronic acid may also be used. Such compositions can affect the physical state, stability, in vivo release rate and in vivo clearance rate of the proteins and derivatives of the present invention. See, e.g., Remington: The Science and Practice of Pharmacy, 22nd Ed., Pharmaceutical Press, PA (2013). The compositions may be prepared in liquid form, or may be a dry powder, such as a lyophilized form.

[0127] It will be understood that the pharmaceutical composition provided according to the present invention can be administered by any means known in the art.The pharmaceutical composition for administration is administered by injection, orally, topically, or by pulmonary or nasal route.For example, antisense oligomer can be delivered by topical, intravenous, intraarterial, intraperitoneal, intramuscular or subcutaneous administration route.The suitable route can be determined by those skilled in the art according to the condition of the subject being treated.

[0128] Formulations for topical administration include those in which the oligomer of the present disclosure is mixed with topical delivery agents such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Lipids and liposomes include neutral (e.g., dioleoyl phosphatidyl DOPE ethanolamine, dimyristoyl phosphatidylcholine DMPC, distearoyl phosphatidylcholine), negative (e.g., dimyristoyl phosphatidyl glycerol DMPG) and cationic (e.g., dioleoyl tetramethyl aminopropyl DOTAP and dioleoyl phosphatidyl ethanolamine DOTMA). For topical or other administration, the oligomer of the present disclosure may be encapsulated or complexed in liposomes, particularly complexed with cationic liposomes. Alternatively, the oligomer may be complexed with lipids, particularly cationic lipids. Fatty acids and esters, their pharma- ceutically acceptable salts, and their uses are further described in U.S. Patent No. 6,287,860 and / or U.S. patent application Ser. No. 09 / 315,298, filed May 20, 1999.

[0129] In certain embodiments, the antisense oligomers of the present disclosure can be delivered by topical or transdermal methods (e.g., by incorporating the antisense oligomer in an emulsion, for example, with such antisense oligomers optionally packaged in liposomes). Such topical or transdermal and emulsion / liposome-mediated delivery methods have been described in the art for delivery of antisense oligomers, for example, in U.S. Patent No. 6,965,025.

[0130] The antisense oligomers described herein can also be delivered via implantable devices, the design of which is an art-recognized process, such as the synthetic implant designs described in U.S. Patent No. 6,969,400.

[0131] Compositions and formulations for administration, including injection, local delivery and implants, may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives, such as, but not limited to, penetration enhancers, carrier compounds and other pharma- ceutically acceptable carriers or excipients.

[0132] Delivery of therapeutically useful amount of antisense oligomer can be achieved by previously published methods. For example, delivery of antisense oligomer can be by a composition comprising a mixture of antisense oligomer and effective amount of block copolymer. One example of this method is described in US Patent Application US20040248833. Other methods of delivering antisense oligomer to nucleus are described in Mann CJ et al. (2001) Proc, Natl. Acad. Science, 98(1) 42-47, and Gebski et al. (2003) Human Molecular Genetics, 12(15): 1801-1811. Methods of introducing nucleic acid molecules into cells as naked DNA or by expression vectors complexed to lipid carriers are described in US Patent No. 6,806,084.

[0133] Antisense oligomers can be introduced into cells using art-recognized techniques (e.g., transfection, electroporation, fusion, liposomes, colloidal polymer particles, and viral and non-viral vectors, and other means known in the art).The delivery method selected depends at least on the cells to be treated and the location of the cells, and will be clear to those skilled in the art.For example, localization can be achieved by liposomes with specific markers on the surface to direct the liposomes, direct injection into tissues containing target cells, specific receptor-mediated uptake, etc.

[0134] It may be desirable to deliver antisense oligomers in colloidal dispersion systems.Colloidal dispersion systems include macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes or liposome preparations.These colloidal dispersion systems can be used to prepare therapeutic pharmaceutical compositions.

[0135] Liposomes are artificial membrane vesicles that are useful as in vitro and in vivo delivery vehicles. These formulations can have net cationic, anionic or neutral charge characteristics, which can be useful for in vitro, in vivo and ex vivo delivery methods. It has been shown that large unilamellar vesicles can encapsulate a significant proportion of aqueous buffer containing large macromolecules. RNA and DNA can be encapsulated in the aqueous interior and delivered to cells in a biologically active form (Fraley, et al., Trends Biochem.Sci.6:77,1981).

[0136] For liposomes to be efficient gene transfer vehicles, the following characteristics should be present: (1) highly efficient encapsulation of the desired antisense oligomer without compromising biological activity; (2) preferential and substantial binding to target cells compared to non-target cells; (3) highly efficient delivery of the aqueous contents of the vesicle to the cytoplasm of the target cells; (4) accurate and effective expression of genetic information (Mannino, et al., Biotechniques, 6:682, 1988). The composition of liposomes is usually a combination of phospholipids, especially high phase transition temperature phospholipids, usually with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical properties of liposomes depend on pH, ionic strength, and the presence of divalent cations. Cationic liposomes are positively charged liposomes that are believed to interact with negatively charged DNA molecules to form stable complexes. pH-sensitive or negatively charged liposomes are believed to entrap DNA rather than complex with it. Both cationic and non-cationic liposomes have been used to deliver DNA to cells.

[0137] Liposomes also include "sterically stabilized" liposomes, which term, as used herein, refers to liposomes that contain one or more specialized lipids that, when incorporated into liposomes, result in an extended circulation life compared to liposomes that lack such specialized lipids. Examples of sterically stabilized liposomes are those in which a portion of the vesicle-forming lipid portion of the liposome contains one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as polyethylene glycol (PEG) moieties. Liposomes and their uses are further described in U.S. Patent No. 6,287,860.

[0138] As is known in the art, antisense oligomers can be delivered using, for example, methods involving liposome-mediated uptake, lipid conjugates, polylysine-mediated uptake, nanoparticle-mediated uptake, and receptor-mediated endocytosis, as well as additional non-endocytotic delivery modalities known in the art, such as microinjection, permeabilization (e.g., streptolysin-O permeabilization, anionic peptide permeabilization), electroporation, and various non-invasive non-endocytotic delivery methods (see Dokka and Rojanasakul, Advanced Drug Delivery Reviews 44, 35-49, incorporated by reference in its entirety).

[0139] Antisense oligomers can also be combined with other pharmaceutically acceptable carriers or diluents to produce pharmaceutical compositions.Suitable carriers and diluents include isotonic saline, such as phosphate buffered saline.Compositions can be formulated for topical, parenteral, intramuscular, intravenous, subcutaneous, intraocular, oral, or transdermal administration.

[0140] The described routes of administration are intended only as a guide, as one of skill in the art can readily determine the optimum route of administration and any dosage for any particular subject and disease or pathology.

[0141] Several approaches have been attempted to introduce functional new genetic material into cells, both in vitro and in vivo (Friedmann (1989) Science, 244:1275-1280). These approaches include incorporation of the gene to be expressed into modified retroviruses (Friedmann (1989) supra; Rosenberg (1991) Cancer Research 51(18), supra:5074S-5079S); incorporation into nonretroviral vectors (Rosenfeld, et al. (1992) Cell, 68:143-155; Rosenfeld, et al. (1991) Science, 252:431-434); or delivery of transgenes linked to heterologous promoter-enhancer elements via liposomes (Friedmann (1989) supra; Brigham, et al. (1989) Am. J. Med. Sci., 298:278-281; ​​Nabel, et al. (1990) Science, 249:1285-1288; Hazinski, et al. al. (1991) Am. J. Resp. Cell Molec. Biol., 4:206-209; and Wang and Huang (1987) Proc. Natl. Acad. Sci. (USA), 84:7851-7855); coupling to ligand-specific cation-based transport systems (Wu and Wu (1988) J. Biol. Chem., 263:14621-14624) or the use of naked DNA, expression vectors (Nabel et al. (1990), supra; Wolff et al. (1990) Science, 247:1465-1468). Direct injection of transgenes into tissues results in only localized expression (Rosenfeld (1992) supra; Rosenfeld et al. (1991) supra; Brigham et al. (1989) supra; Nabel (1990) supra; and Hazinski et al. (1991) supra).Brigham et al. (Am. J. Med. Sci. (1989) 298:278-281 and Clinical Research (1991) 39 (abstract)) reported in vivo transfection of only the lungs of mice after intravenous or intratracheal administration of DNA-liposome complexes. Examples of review articles on human gene therapy procedures are: Anderson, Science (1992) 256:808-813; Barteau et al. (2008), Curr Gene Ther; 8(5):313-23; Mueller et al. (2008). Clin Rev Allergy Immunol; 35(3):164-78; Li et al. (2006) Gene Ther., 13(18):1313-9; Simoes et al. (2005) Expert Opin Drug Deliv; 2(2):237-54.

[0142] The antisense oligomers of the present invention include any pharma- ceutically acceptable salts, esters or salts of such esters, or any other compounds that can provide (directly or indirectly) a biologically active metabolite or residue thereof when administered to an animal, including a human.Thus, by way of example, the present disclosure also relates to prodrugs and pharma-ceutically acceptable salts of the compounds of the present invention, pharma-ceutically acceptable salts of such prodrugs, and other bioequivalents.

[0143] The term "pharmaceutically acceptable salts" refers to physiologically and pharma- ceutically acceptable salts of compounds of the present invention, i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects. In the case of oligomers, preferred examples of pharma- ceutically acceptable salts include, but are not limited to, (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine; (b) acid addition salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like; (c) salts formed with organic acids, such as acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chloride, bromide, and iodine. The pharmaceutical compositions of the present invention may be administered in several ways, depending on whether local or systemic treatment is desired and on the area to be treated. Administration may be by topical (including ocular and mucosal membranes, as well as rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer, intratracheal, intranasal, epidermal and transdermal), oral or parenteral routes. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intraocular or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligomers having at least one 2'-O-methoxyethyl modification are believed to be particularly useful for administration.

[0144] The pharmaceutical preparation of the present invention, which can be conveniently provided in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry.Such techniques include the step of bringing active ingredient into association with pharmaceutical carrier(s) or excipient(s).Generally, the preparation is prepared by bringing active ingredient into association uniformly and intimately with liquid carrier or finely divided solid carrier or both, and then shaping the product as necessary.

[0145] use According to another aspect of the present invention, there is provided the use of one or more antisense oligomers as described herein in the manufacture of a medicament for regulating or controlling a disease or pathology associated with PPIF gene expression.

[0146] The present invention also provides the use of a purified and isolated antisense oligomer as described herein for the manufacture of a medicament for treating, preventing or ameliorating a disease or pathology associated with PPIF gene expression.

[0147] Also provided is the use of a purified and isolated antisense oligomer as described herein for the manufacture of a medicament for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression.

[0148] Also provided is the use of one or more antisense oligomers described herein to regulate or control a disease or pathology associated with PPIF gene expression.

[0149] The present invention also provides the use of the purified and isolated antisense oligomers described herein to treat, prevent, or ameliorate a disease or pathology associated with PPIF gene expression.

[0150] Also provided is the use of a purified and isolated antisense oligomer as described herein to treat, prevent, or ameliorate the effects of a disease or pathology associated with PPIF gene expression.

[0151] Preferably, the PPIF gene expression associated disease or pathology is selected from the list including ischemia-reperfusion associated injury, oxidative associated injury, inflammation associated injury and trauma associated injury (affecting the liver, brain, heart, lungs, pancreas and kidneys), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic diseases (NAFLD / NASH and obesity), skeletal muscle diseases, and inflammatory diseases.

[0152] According to a still further aspect thereof, the present invention extends to cDNA or cloned copies of the antisense oligomer sequences of the invention, as well as vectors containing the antisense oligomer sequences of the invention. The present invention further extends to cells containing such sequences and / or vectors.

[0153] kit Also provided are kits for treating, preventing or ameliorating the effects of a disease or pathology associated with PPIF gene expression in a patient, comprising at least an antisense oligomer as described herein, and combinations or cocktails thereof, packaged in a suitable container together with instructions for use thereof.

[0154] In a preferred embodiment, the kit contains at least one antisense oligomer described herein or shown in Table 3, or set forth in SEQ ID NOs: 1-44, more preferably SEQ ID NOs: 35 or 37, or a cocktail of antisense oligomers described herein. The kit may also contain peripheral reagents such as buffers, stabilizers, etc.

[0155] Thus, provided is a kit for treating, preventing or ameliorating a disease or pathology associated with PPIF gene expression in a patient, comprising at least an antisense oligomer, and combinations or cocktails thereof, as described herein or shown in Table 3, packaged in a suitable container together with instructions for use thereof.

[0156] Also provided is a kit for treating, preventing or ameliorating a disease or pathology associated with PPIF expression in a patient, the kit comprising at least an antisense oligomer selected from the group consisting of any one or more of SEQ ID NOs: 1-44, more preferably SEQ ID NOs: 35 or 37, and combinations or cocktails thereof, packaged in a suitable container together with instructions for use thereof.

[0157] Preferably, the disease or pathology is selected from the list comprising ischemia-reperfusion-related injury, oxidative-related injury, inflammation-related injury and trauma-related injury (affecting the liver, brain, heart, lungs, pancreas and kidneys), neurodegeneration (Alzheimer's disease, Parkinson's disease, motor neuron disease), diabetes, metabolic disease (NAFLD / NASH and obesity), skeletal muscle disease and inflammatory disease. More preferably, the disease or pathology is a liver disease selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or hepatocellular carcinoma.

[0158] The contents of the kit can be lyophilized and the kit can further contain a solvent suitable for reconstitution of the lyophilized components. Individual components of the kit can be packaged in separate containers and associated with such containers can be a notice in a form prescribed by a government agency regulating the manufacture, use, or sale of pharmaceutical or biological products, the notice reflecting approval by the agency of the manufacture, use, or sale for human administration.

[0159] When the components of the kit are provided in one or more liquid solutions, the liquid solution can be an aqueous solution, for example a sterile aqueous solution. For in vivo use, the expression construct can be formulated into a pharma-ceutically acceptable injectable composition. In this case, the container means can itself be an inhaler, syringe, pipette, eye dropper, or other such device, from which the formulation can be applied to the affected area of ​​the subject, such as the lungs, injected into the subject, or even applied to and mixed with other components of the kit.

[0160] In one embodiment, the kit of the present invention comprises a composition comprising a therapeutically effective amount of an antisense oligomer capable of binding to a selected target on the PPIF gene transcript and altering pre-mRNA splicing in the PPIF gene transcript or a portion thereof. In an alternative embodiment, the formulation is pre-measured, pre-mixed, and / or pre-packaged.

[0161] The kit of the present invention may also include instructions designed to facilitate user compliance. Instructions as used herein refers to any label, insert, etc., and may be placed on one or more surfaces of the packaging material, or the instructions may be provided on a separate sheet, or any combination thereof. For example, in one embodiment, the kit of the present invention includes instructions for administering the formulation of the present invention. In one embodiment, the instructions indicate that the formulation of the present invention is suitable for treating a disease or pathology associated with PPIF gene expression. Such instructions may also include dosage instructions as well as administration instructions.

[0162] Antisense oligomer and suitable excipient can be packaged separately, so that practitioner or user can formulate the components into pharmaceutically acceptable composition as needed.Alternatively, antisense oligomer and suitable excipient can be packaged together, so that practitioner or user needs to minimize the formulation.In any case, packaging should maintain the chemical, physical and aesthetic integrity of active ingredient.

[0163] general Those skilled in the art will understand that the invention described herein is susceptible to variations and modifications other than those specifically described.The invention includes all such variations and modifications.The invention also includes all of the steps, features, formulations and compounds referred to or indicated herein, individually or collectively, and any and all combinations or any two or more steps or features.

[0164] Each document, reference, patent application, or patent cited in this document is expressly incorporated herein by reference in its entirety, meaning that it should be read and considered by the reader as part of this document. It is for the sake of brevity only that documents, references, patent applications, or patents cited in this document are not repeated in this document.

[0165] Any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned in this specification, or in any document incorporated by reference herein, are incorporated herein by reference and may be used in the practice of this invention.

[0166] The scope of the present invention is not limited by any of the specific embodiments described herein. These embodiments are for illustrative purposes only. Functionally equivalent products, formulations and methods are clearly within the scope of the invention described herein.

[0167] The invention described herein can include one or more ranges of values ​​(e.g., size, displacement, field strength, etc.). A range of values ​​is understood to include all values ​​within the range, including the values ​​defining the range and the values ​​adjacent to the range that produce the same or substantially the same results as the values ​​immediately adjacent to the values ​​defining the boundaries to the range. Thus, unless indicated to the contrary, the numerical parameters set forth in this specification and claims are approximations that may vary depending on the desired properties sought to be obtained by the present invention. Thus, "about 80%" means "about 80%" and also means "80%". At the very least, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

[0168] Throughout this specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising" are understood to mean the inclusion of a recited integer or group of integers but not the exclusion of any other integer or group of integers. Also, in this disclosure, particularly in the claims and / or paragraphs, it is noted that terms such as "comprises," "comprised," "comprising," and the like can have the meaning ascribed to them in U.S. patent law. For example, they can mean "includes," "included," "including," and the like. Terms such as "consisting essentially of" and "consists essentially of" have the meaning ascribed to them in U.S. patent law, for example, they allow for elements not expressly recited, but exclude elements found in the prior art or that affect a basic or novel characteristic of the invention.

[0169] Other definitions of selected terms used herein can be found in the detailed description of the present invention and can be applied throughout.Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs.The term "active agent" can mean one active agent or can include two or more active agents.

[0170] The sequence identification numbers ("SEQ ID NOs"), including the nucleotide and amino acid sequence information contained herein, are collected at the end of the description and have been prepared using the program Patentln Version 3.0. Each nucleotide or amino acid sequence is identified in the sequence listing by a numeric index. <210> followed by a sequence identifier (e.g., <210> 1. <210> 2, etc. The length of each nucleotide or amino acid sequence, the type of sequence, and the source organism are each identified by a numeric index field. <211> , <212> and <213> The nucleotide and amino acid sequences referred to herein are represented by the information provided in the numeric index fields. <400> followed by a sequence identifier (e.g., <400> 1. <400> 2, etc.).

[0171] To distinguish between different antisense oligomers, an antisense oligomer nomenclature system has been proposed and published (see Mann et al., (2002) J Gen Med 4, 644-654). This nomenclature has become particularly relevant when testing several slightly different antisense oligomers all directed to the same target region, as shown below: H # A / D(x:y) The first letter indicates the species (eg, H: human, M: mouse). "#" indicates the target exon number "A / D" indicates the acceptor or donor splice sites at the beginning and end of the exon, respectively. (xy) represent annealing coordinates, with "-" or "+" indicating intron or exon sequences, respectively. As an example, A(-6+18) indicates the last 6 bases of the intron preceding the target exon and the first 18 bases of the target exon. These coordinates are preceded by an "A" because the nearest splice site is the acceptor. Annealing coordinates at the donor splice site can be written as D(+2-18), with the last 2 exon bases and the first 18 intron bases corresponding to the annealing site of the antisense oligomer. Annealing coordinates for an entire exon are represented as A(+65+85), a site between the 65th and 85th nucleotides from the start of that exon, inclusive.

[0172] The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention, It is understood that these methods in no way serve to limit the true scope of the invention, but rather are presented for illustrative purposes. EXAMPLES

[0173] Example 1 Antisense oligomers (ASON) mediated exon skipping and induced frameshifting in PPIF [Table 7] method cell culture All experiments were performed with the cell lines HepG2 and Huh-7 cells (CellBank Australia). Cultures were grown in GluMax Dulbecco's Modified Eagle's Medium (DMEM; Gibco supplemented with 10% fetal bovine serum [Serana], penicillin [10 units / ml] and streptomycin [10ug / ml] at 37°C in 5% CO2). Cells were maintained in flasks (T-25) and subcultured every 3-4 days at a ratio of 1:6. Cells were not used beyond passage 25.

[0174] Transfection The day before transfection of HepG2 cells, the medium was removed from the T-25 flask and the cell monolayer was trypsinized (TrypLE™ Express containing EDTA; Invitrogen) for 15 min at 37° C. in 5% CO2. The cells were transferred to a 5 ml sterile tube using a sterile transfer pipette and released from the clumps by repeated vigorous passage (10 times) through an 18-gauge needle. The cells were transferred to a sterile 15 ml conical centrifuge tube and resuspended in fresh DMEM containing serum. After centrifugation at 750 rpm for 2 min, the medium was removed and the cell pellet was resuspended in 2 ml of fresh DMEM. 10 ul was removed and mixed with an equal volume of trypan blue (0.05%) and the cell concentration was determined using a hemocytometer. The cells were diluted in DMEM with serum / antibiotics and seeded at approximately 50,000 cells / well in 500 ul in a 24-well plate. The next day (approximately 24 hours later), growth medium was removed and replaced with 500ul OptiMEM, treated with ASON (to the desired final concentration of 1000nM, 500nM or 250nM) and mixed with RNAiMax (Invitrogen) according to the manufacturer's instructions. Briefly, ASON was combined with serum-free OptiMEM and RNAiMax (Xul per well of each for 24 hours) and incubated for 5 minutes. The ASON / RNAiMax mixture was added dropwise to each well, mixed gently, and incubated for 24 or 48 hours before RNA (for RT-PCR) or protein extraction (for Western blotting). For protein collection and prevention of further cell growth, OptiMEM / transfection reagent was replaced with DMEM supplemented with 1% FCS and antibiotics after 24 hours.

[0175] RNA extraction The medium was removed and total RNA was extracted using either the RNeasy Mini Kit (Qiagen) or the total RNA Favorgen blood / cell culture column kit according to the column method according to the manufacturer's instructions. Total RNA was eluted in sterile water and quantified using a Nanodrop instrument (Invitrogen).

[0176] Annealing and synthesis of complementary DNA (cDNA) For the annealing step, mix total RNA (250-500 ng) with 0.125 ug of oligo(dT) in WFI. 15 (Promega), incubated at 70 °C for 5 min, and rapidly cooled by quenching on ice (0–4 °C) for 5 min. For first strand synthesis, the annealed primer-template was gently mixed with 5 × M-MLV RT buffer (Promega), 10 mM dNTP mix (Promega) and MMLV reverse transcriptase, RNase H Minus, Point Mutant (Promega). The reaction was incubated at 40 °C for 10 min, followed by 50 °C for 60 min. The reaction was inactivated by heating to 70 °C for 15 min. Complementary DNA was used as template for PCR amplification or was otherwise stored at -20 °C.

[0177] Second strand synthesis and PCR amplification In a 20 ul reaction volume, 2 ul of cDNA was combined with CYPD primers (Table 4) and sterile water and an equal volume of GO-TAQ Clear 2x Master Mix. The PCR amplification reaction proceeded according to the cycling conditions shown in Table 5 below. [Table 4] [Table 5]

[0178] Gel electrophoresis PCR reactions (20 ul) were mixed with 4 ul of 6x gel loading buffer and electrophoresed in 2-3.5% agarose gels at 90 V for 90 min using a 1x TAE or TBE buffer system. Gels were pre-stained with Syber Safe DNA gel stain (Thermo Fisher) and bands were visualized and imaged using a Chemi-Doc System (Bio-Rad Laboratories). A 100 bp molecular weight ladder (Axygen) was included for band size estimation.

[0179] Sequencing Analysis To confirm exon skipping after ASON treatment, PCR bands were excised from agarose gels, purified and subjected to DNA sequencing (by the Australian Genome Resource Facility (AGRF) or by the State Agricultural Biotechnology Centre).

[0180] Protein gel electrophoresis Proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; TGX unstained system, Bio-Rad, USA) using a Mini-Protean Tetra Cell assembly (Bio-Rad Laboratories). The gels used were 4%-15% gradient Mini-Protean TGX precast gels (Bio-Rad Laboratories). A total of 5ul of protein and sterile DD water were combined with 4.75ul of Laemmli sample buffer (Bio-Rad Laboratories) and 0.25ul of dithiothreitol (DTT) and heated at 70°C for 10 minutes. Precision Plus prestained protein ladder (Bio-Rad) was used as molecular weight standard. Samples (10ul) and markers were loaded onto the pre-rinsed gel and run at 200 volts for 45 minutes. Protein bands were visualized using a ChemDoc System (Bio-Rad) fitted with appropriate filters.

[0181] Western transfer and immunoblotting Proteins were transferred from SDS-PAGE gels to 0.45um low-fluorescence PVDF membranes using a Turbo-Blot Turbo (BioRad-Laboratories) transfer apparatus using Turbo-Blot Turbo transfer buffer (BioRad Laboratories) 20% ethanol. Membranes were washed with Tris-buffered saline (TBS: Tris 20mM; NaCl 200mM; pH 7.6) and blocked for 1 hour in TBS-T (TBS with 0.1% Tween-20 + chicken ovalbumin [Sigma; 1mg / ml]). Membranes were incubated overnight at 4°C with gentle rocking in primary antibody (mouse monoclonal anti-cyclophilin F, 1:5000) diluted in TBS-T. Membranes were rinsed three times with TBS-T and incubated for 2 hours at room temperature in TBS-T containing secondary antibody (goat anti-mouse IgG conjugated with HRP enzyme 1:25,000). Membranes were rinsed three times with TBS-T and then washed three more times for 5 min in TBS. Protein bands were detected using ECL reagents Clarity (BioRad) according to the manufacturer's instructions. Blots were imaged using a ChemiDoc-MP system (Bio-Rad) using chemiluminescence and fluorescence imaging settings. CYPD expression was quantified using Image Lab (Bio-Rad) imaging software and normalized for protein loading using unstained gel images. [Table 6]

[0182] result Antisense RNA sequences were designed to interact with the full-length pre-mRNA CYPB transcript and disrupt normal splicing such that either exon 3 or exon 4 was deleted from the mature mRNA transcript. Based on the PPIF reference sequence (NM_005729): exon 2 deletion was predicted to induce six premature downstream stop codons; exon 3 deletion was predicted to induce four premature downstream stop codons; exon 4 deletion was predicted to induce four premature downstream stop codons, and exon 5 deletion was predicted to induce three premature downstream stop codons.

[0183] For exon 2 deletions, six ASOs (SEQ ID NOs: 1-6) were designed to span either the 5' prime acceptor site in exon 3, the 3' donor site in exon 3 and / or a site within exon 2. In these experiments, which were repeated at least once, Hep G2 cells were transfected with 500 nM of each antisense, synthesized with 2'-O-methyl chemistry. Total RNA was collected 24 h after transfection and RT-PCR analysis (amplified with primer set sequence 46 / 47) was performed to assess the degree of exon skipping (Figure 1a). Sequences CDm2.1, 2.2, 2.3 and 2.5 induced comparable levels of exon 2 skipping, with deletion of exon 2 resulting in a PCR product consistent with the expected size of 31 bp (Figure 1b).

[0184] For exon 3 deletions, seven ASOs (sequence numbers 7-13) were designed to span either the 5' prime acceptor site of exon 3, the 3' donor site of exon 3 and / or a site within exon 3. In these experiments, which were repeated at least once, Hep G2 cells were transfected with 500 nM of each antisense, synthesized with 2'-O-methyl chemistry. Total RNA was collected 24 h after transfection and RT-PCR analysis (amplified with primer set sequence 46 / 47) was performed to assess the degree of exon skipping (Figure 1a). Sequences CDm3.3 and CDm3.4 induced comparable levels of exon 4 skipping, with deletion of exon 4 resulting in a PCR product consistent with the expected size of 89 bp (Figure 1c).

[0185] For exon 4 deletion, six ASOs (sequence numbers 19-25) were designed to span either the 5' prime acceptor site in exon 3, the 3' donor site in exon 4 and / or a site within exon 4. In these experiments, which were repeated at least once, Hep G2 cells were transfected with 500 nM of each antisense, synthesized with 2'-O-methyl chemistry. Total RNA was collected 24 h after transfection and RT-PCR analysis (amplified with primer set sequence 46 / 47) was performed to assess the degree of exon skipping (Figure 2a). Sequences CDm4.3 and CDm4.4 induced comparable levels of exon 4 skipping, with deletion of exon 4 resulting in a PCR product consistent with the expected size of 97 bp (Figure 2b).

[0186] For exon 5 deletions, five ASOs (sequence numbers 32-36) were designed to span either the 5' prime acceptor site of exon 3, the 3' donor site of exon 5 and / or a site within exon 5. In these experiments, which were repeated at least once, Hep G2 cells were transfected with 500 nM of each antisense, synthesized with 2'-O-methyl chemistry. Total RNA was collected 24 h after transfection and RT-PCR analysis (amplified with primer set sequences 46 / 47) was performed to assess the degree of exon skipping (Figure 2b). Sequences CDm5.3 and CDm5.4 induced comparable levels of exon 5 skipping, with deletion of exon 5 resulting in a PCR product consistent with the expected size of 76 bp (Figure 2c).

[0187] To improve the degree of exon 3 skipping, five overlapping ASOs (sequence numbers 14-18) were designed by microwalking across the pre-mRNA region targeted by CDm3.4. The strategy involved shifting the 5' and 3' of the region targeted by CDm3.4 in 3 bp increments while limiting the total oligonucleotide length to 25 bases. In these experiments, which were repeated at least once, Hep G2 cells were transfected with antisenses synthesized with MOE chemistry (250 nM). Total RNA was collected 24 h after transfection and exon skipping was assessed using RT-PCR analysis (using primer set sequence 49 / 50) (Figure 3). Non-transfected cultures (denoted NTC) were used as wild-type mRNA controls. The percentage of exon 3 skipping was quantified using ImageLab (Biorad). The best ASO sequence was CDm3.45 (SEQ ID NO: 18), which induced nearly complete skipping, while the next best ASO sequence was 3.44, which induced approximately 80% skipping.

[0188] To improve the degree of exon 4 skipping, six overlapping ASOs (sequence numbers 26-31) were designed by microwalking across the pre-mRNA region targeted by CDm4.4. The strategy involved shifting the 5' and 3' of the region targeted by CDm4.4 in 3 bp increments while limiting the total oligonucleotide length to 25 bases. In these experiments, which were repeated at least once, Hep G2 cells were transfected with antisenses synthesized with MOE chemistry (250 nM). Total RNA was collected 24 h after transfection and exon skipping was assessed using RT-PCR analysis (using primer set sequence 49 / 50) (Figure 4). Non-transfected cultures (denoted NTC) were used as wild-type mRNA controls. The percentage of exon 4 skipping was quantified using ImageLab (Biorad). The best ASO sequences were CDm4.4 (SEQ ID NO: 22) and CDm4.41 (SEQ ID NO: 18), which induced nearly complete skipping with no apparent residual FL-CYPD. In contrast, ASOs CDm4.42-CDm4.46 induced skipping estimated to be greater than 90%.

[0189] To improve the degree of exon 5 skipping, two sets of overlapping ASO sequences were designed by microwalking across the pre-mRNA regions targeted by CDm5.3 (5 in SEQ ID NOs: 37-41) and CDm5.4 (3 in SEQ ID NOs: 42-44). This strategy involved shifting the 5' and 3' of the regions targeted by CDm5.3 and CDm5.4 in 3 bp increments while limiting the total oligonucleotide length to 25 bases. In these experiments, which were repeated at least once, Hep G2 cells were transfected with antisense synthesized with MOE chemistry (250 nM). Total RNA was collected 24 h after transfection and exon skipping was assessed using RT-PCR analysis (using primer set sequence 49 / 50) (Figure 5). Non-transfected cultures (denoted as NTC) were used as wild-type mRNA controls. The percentage of exon 5 skipping was quantified using ImageLab (Biorad). ASO sequences CDm5.4, CDm5.41, CDm5.42, and CDm5.43 all induced complete skipping with no apparent residual FL-CYPD. In contrast, ASOs CDm5.3, CDm5.31, CDm5.32, CDm5.33, and CDm5.34 induced an estimated >90% skipping, whereas CDm5.35 induced >60% skipping.

[0190] The best ASOs (CDm3.45, CDm4.4, CDm4.41, CDm5.3, CDm5.31 CDm5.4, CDm5.41, CDm5.42) and the scrambled control 953 (SEQ ID NO: 45) were transfected into HepG2 cultures at 250 nM using Lipofectamine RNAiMax. Total RNA was collected 24 hours after transfection and RT-PCR analysis (using primer set sequence 49 / 50) was performed to determine the extent of exon skipping (Figure 4a). Quantification of exon skipping by each ASO was as follows: CDm3.45 induced 45.3% skipping of exon 3; CDm4.4 induced 77.3% skipping of exon 4; CDm4.41 induced 92.1% skipping of exon 4; CDm5.4 induced 98.2% skipping of exon 5; CDm5.41 induced 95.2% skipping of exon 5; CDm5.42 induced 93.6% skipping of exon 5; CDm5.3 induced 94.5% skipping of exon 5; CDm5.31 induced 93.0% skipping of exon 5. Dual transfection plates (transfection mixture was replaced with DMEM containing 1% FCS / antibiotics at 24 h) were incubated for a further 48 h and cell lysates were harvested for Western blot analysis. Western blot analysis confirmed that CYPD protein was reduced 72 hours after transfection in all ASO-treated cultures except CDm3.45 (Figure 4b and Figure 4c). Cyclophilin D protein band density was normalized to NTC (mock-transfected) control cultures (Figure 4c). Treatment with ASOs CDm5.4 and CDm5.31 reduced CYPD expression to 38% and 54.8%, respectively. Treatment with other ASOs reduced CYPD expression as indicated in brackets: CDm4.4 (71.2%); CDm4.41 (59.1%); CDm5.41 (58.9%); CDm5.42 (70.9%) and; CDm5.3 (67.6%).Scrambled ASO(953), which served as a treatment control, induced a 10% decrease in CYPD compared to NTC, although the cause of this decrease in CYPD protein was not investigated but could be a nonspecific effect on cellular protein output.

Claims

1. An isolated or purified antisense oligomer having an altered backbone structure for altering pre-mRNA splicing in a PPIF gene transcript or a portion thereof.

2. The antisense oligomer of claim 1, which induces non-productive splicing or dysfunction in the PPIF gene transcript or a portion thereof.

3. 2. The antisense oligomer of claim 1, selected from the list comprising SEQ ID NOs: 1 to 44 with modified backbone structures and sequences having at least 95% sequence identity to SEQ ID NOs: 1 to 44 with modified backbone structures.

4. The antisense oligomer of claim 1, wherein the antisense oligomer comprises one or more nucleotide positions that are subjected to an alternative chemistry or modification selected from the list including: (i) a modified backbone structure; (ii) a modified sugar moiety; (iii) resistance to RNase H; (iv) an oligomer mimetic chemistry.

5. 2. The antisense oligomer of claim 1, wherein the antisense oligomer is further modified by (i) chemical conjugation to a moiety; and / or (ii) tagging with a cell-penetrating peptide.

6. 2. The antisense oligomer of claim 1, wherein any uracil (U) present in the nucleotide sequence is replaced by thymine (T).

7. 2. The antisense oligomer of claim 1, which acts to induce skipping of one or more exons of the PPIF gene transcript or a portion thereof.

8. 1. A method for modulating splicing in a PPIF gene transcript, comprising: A method comprising the steps of: a) providing one or more antisense oligomers of any one of claims 1 to 7 and allowing the oligomers to bind to a target nucleic acid site.

9. 1. A pharmaceutical, prophylactic or therapeutic composition for treating, preventing or ameliorating the effects of a disease associated with PPIF expression in a patient, comprising: a) one or more antisense oligomers according to any one of claims 1 to 7, and b) one or more pharma- ceutically acceptable carriers and / or diluents; 23. A pharmaceutical, prophylactic or therapeutic composition comprising:

10. 1. A method for treating, preventing or ameliorating the effects of a disease associated with PPIF expression, comprising: A method comprising the step of: a) administering to a patient an effective amount of one or more antisense oligomers according to any one of claims 1 to 7, or a pharmaceutical composition comprising one or more antisense oligomers.

11. Use of the purified and isolated antisense oligomer of any one of claims 1 to 7 for the manufacture of a medicament for treating, preventing or ameliorating the effects of a disease associated with PPIF expression.

12. A kit for treating, preventing or ameliorating the effects of a disease associated with PPIF expression in a patient, comprising at least an antisense oligomer described in any one of claims 1 to 7 and combinations or cocktails thereof, packaged in a suitable container together with instructions for use thereof.

13. The composition according to claim 9, the method according to claim 8 or 10, the use according to claim 11 or the kit according to claim 12, wherein the disease or pathology associated with PPIF expression is selected from the list comprising ischemia-reperfusion-related damage, oxidative damage, inflammation-related damage and trauma-related damage, neurodegeneration, diabetes, metabolic diseases, skeletal muscle diseases and inflammatory diseases.

14. The composition according to claim 9, the method according to claim 8 or 10, the use according to claim 11 or the kit according to claim 12, wherein the subject having the disease or pathology associated with PPIF expression is a human.

15. 2. The antisense oligomer of claim 1, selected from the list comprising SEQ ID NO: 35 or 37.